The Cigna Group has announced a restructuring of its Board of Directors' committee structure, effective January 1, 2026. As part of the reorganization, the Compliance Committee will be dissolved following the sale of several business units earlier in 2025, with its responsibilities transferred to the full Board and other committees. The Audit Committee will be renamed the Audit and Compliance Committee, taking on broader enterprise compliance oversight. The Corporate Governance Committee will now oversee the company's ethics program and public clinical reporting. Additionally, technology oversight will be consolidated into the newly renamed Finance and Technology Committee, which will handle technology strategy, information security, and artificial intelligence. Oversight of clinical compliance and patient experience will become a responsibility of the full Board. These changes aim to align committee duties with Cigna's evolving strategic priorities and strengthen corporate governance.